KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash & Equivalents (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Cash & Equivalents readings, the most recent being $201000.0 for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 99.81% to $201000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $201000.0, a 99.81% decrease, with the full-year FY2025 number at $201000.0, down 99.81% from a year prior.
  • Cash & Equivalents hit $201000.0 in Q4 2025 for Biocryst Pharmaceuticals, down from $579000.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $504.4 million in Q4 2021 to a low of $201000.0 in Q4 2025.
  • Median Cash & Equivalents over the past 5 years was $4.3 million (2021), compared with a mean of $78.4 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 22610.0% in 2021 and later crashed 99.81% in 2025.
  • Biocryst Pharmaceuticals' Cash & Equivalents stood at $504.4 million in 2021, then tumbled by 39.58% to $304.8 million in 2022, then crashed by 63.7% to $110.6 million in 2023, then decreased by 5.36% to $104.7 million in 2024, then crashed by 99.81% to $201000.0 in 2025.
  • The last three reported values for Cash & Equivalents were $201000.0 (Q4 2025), $579000.0 (Q3 2025), and $492000.0 (Q2 2025) per Business Quant data.